AllinkBio

Executive Summary

AllinkBio is a Shanghai-based biotechnology company founded in 2016, focusing on developing next-generation engineered cell therapies (CAR-T/TCR-T) to treat cancer, particularly solid tumors. The company aims to overcome current limitations in solid tumor treatment by enhancing potency and safety of cell products. As a preclinical stage company with a small employee base, it is privately held and has not disclosed funding or valuation. Despite limited public information, its focus on solid tumors differentiates it from many CAR-T companies targeting hematological malignancies. The biotech landscape in China is competitive, but AllinkBio's approach to next-generation cell therapy could address significant unmet needs. Key potential catalysts include the filing of an Investigational New Drug (IND) application for its lead candidate, presentation of preclinical data at a major conference, or a strategic partnership with a larger pharmaceutical company. However, as a preclinical company with no disclosed pipeline details, the timing and probability of these events are uncertain.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead candidate30% success
• H1 2026Preclinical data release at major conference40% success
• 2026Strategic partnership or collaboration25% success